BCM
MXCT icon

BlueCrest Capital Management’s MaxCyte MXCT Stock Holding History

BlueCrest Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-44,819
Closed -$457K – 319
2021
Q4 		$457K Hold
44,819
– – 0.01% 252
2021
Q3 		$547K Buy
+44,819
New +$676K 0.01% 279

Other funds holding MXCT

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlueCrest Capital Management's MXCT Position: Q1 2022 in Review

BlueCrest Capital Management sold out of MaxCyte (MXCT) in Q1 2022, closing a stake of 44,819 shares — an estimated $457K sold.

BlueCrest Capital Management first reported a position in MXCT in Q3 2021 and held it in 2 quarters. The position peaked at $547K in Q3 2021. 98 funds tracked by Wall St. Rank hold MXCT as of Q1 2022.

  • BlueCrest Capital Management reported no remaining MaxCyte position as of Q1 2022 after selling out during the quarter.
  • BlueCrest Capital Management sold 44,819 MaxCyte shares in Q1 2022, an estimated $457K.
  • BlueCrest Capital Management first reported a position in MaxCyte in Q3 2021 and held it in 2 quarters.
  • BlueCrest Capital Management's MaxCyte position peaked at $547K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held MaxCyte as of Q1 2022.

Based on BlueCrest Capital Management's 13F filing for Q1 2022, filed 16 May 2022.